Pheniramine
| Evidence Level: L3 | Predicted Indications: 3 |
Table of Contents
Pheniramine: From Allergic Symptom Relief to Allergic Urticaria
One-Sentence Summary
Pheniramine is a classical first-generation H1-antihistamine, though a formally documented original indication is not available in the current data pack. The TxGNN model predicts it may be effective for Allergic Urticaria, supported by 1 clinical trial (of limited direct relevance) and 20 literature references — most concerning the chlorpheniramine/dexchlorpheniramine class rather than pheniramine itself.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not established from local licensing data (drug is not marketed); classically used as a first-generation H1-antihistamine for allergic symptoms |
| Predicted New Indication | Allergic Urticaria |
| TxGNN Prediction Score | 99.67% |
| Evidence Level | L3 |
| Market Status | Not Marketed |
| Number of Registrations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism-of-action data for Pheniramine itself is not currently available. Based on known pharmacology, Pheniramine belongs to the first-generation alkylamine H1-antihistamine class, structurally and pharmacologically related to chlorpheniramine and dexchlorpheniramine. H1-receptor antagonism is the established standard-of-care mechanism for treating allergic urticaria, so a class-level rationale for this prediction is plausible.
However, the supporting evidence is largely indirect: the majority of clinical and literature evidence in this evidence pack pertains to chlorpheniramine or dexchlorpheniramine rather than Pheniramine specifically. This represents evidence extrapolated across a drug class rather than drug-specific proof of efficacy. Two literature items (PMID 40125237, 40324831) do reference Pheniramine directly, but describe adverse/hypersensitivity events rather than efficacy in urticaria.
Given the absence of a documented original indication and pheniramine-specific RCT data, the mechanistic plausibility is reasonable but currently unconfirmed at the drug-specific level — this should be treated as a class-effect hypothesis pending dedicated evidence.
Clinical Trial Evidence
| Trial Number | Phase | Status | Enrollment | Key Findings |
|---|---|---|---|---|
| NCT02082054 | Phase 2 | Unknown | 125 | Dose-ranging study of atropine + pseudoephedrine/chlorpheniramine in seasonal allergic rhinitis (TNSS endpoint). Relevance graded C — primarily an atropine-focused trial with chlorpheniramine as a combination comparator; not a direct evaluation of Pheniramine in urticaria, likely retrieval noise. |
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 35652393 | 2024 | Review | Curr Rev Clin Exp Pharmacol | Comprehensive review of chlorpheniramine (CPM), noting historical use in chronic urticaria among other allergic conditions |
| 39265704 | 2024 | Cohort | Eur J Pharm Sci | Comparative inhibition of histamine-induced wheal/flare by oral bilastine vs. parenteral dexchlorpheniramine and a new bilastine formulation |
| 18597008 | 2008 | Cohort | Methods Find Exp Clin Pharmacol | Large-scale surveillance (n=1,742) of sedative profiles across H1-antihistamines, including first-generation agents |
| 40125237 | 2025 | Case Report | Cureus | Immediate hypersensitivity reaction to Pheniramine itself in a patient with multiple drug hypersensitivity syndrome |
| 40324831 | 2025 | Case Report | Indian J Pharmacol | Serious adverse event (loss of consciousness) following concurrent IV pheniramine and hydrocortisone for anaphylaxis management |
| 31852144 | 2019 | Case Report | Medicine | Two cases of chlorpheniramine-induced anaphylaxis plus retrospective pharmacovigilance database review |
| 32641443 | 2020 | Case Report | BMJ Case Rep | Urticaria and angioedema as a prodromal cutaneous manifestation of COVID-19 (disease-context, not drug-specific) |
| 15623181 | 2004 | Preclinical | JPMA | Comparison of chlorpheniramine vs. loratadine effects on isolated rabbit trachea (mechanistic/preclinical) |
| 26179134 | 2015 | Case Report | Contact Dermatitis | Palpebral angioedema and allergic contact dermatitis caused by a cerumenolytic |
| 25372261 | 2014 | Case Report | Cutis | Flurbiprofen-induced unilateral eyelid angioedema |
Safety Considerations
Please refer to the package insert for safety information.
(Note: safety label warnings, contraindications, and drug-drug interaction data are currently unavailable — this is a Blocking-severity data gap per the evidence pack that prevents initial safety screening.)
Conclusion and Next Steps
Decision: Hold
Rationale: Evidence supporting Pheniramine specifically (rather than the broader chlorpheniramine/dexchlorpheniramine class) in allergic urticaria is limited to case reports and indirect class-level studies, corresponding to Evidence Level L3. Combined with a Blocking data gap on TFDA safety labeling (warnings/contraindications), the candidate cannot yet proceed to initial safety screening (S1).
To proceed, the following is needed:
- TFDA/regulatory label data — warnings, contraindications (currently a Blocking gap)
- Drug-specific mechanism of action confirmation for Pheniramine (currently a Data Gap)
- Drug-drug interaction (DDI) profile (current query returned no results)
- Dedicated pheniramine-specific efficacy data in urticaria populations, rather than class-effect extrapolation from chlorpheniramine/dexchlorpheniramine studies
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.